Five names on the radar: KBLB, GPUS, LUCD, XXII and SHFS

DENVER, Colo. (247marketnews.com) — With U.S. crude hovering just above $100 a barrel, 247 Market News is watching Kraig Biocraft Laboratories (OTCQB:KBLB), Hyperscale Data (NYSEAMERICAN:GPUS), Lucid Diagnostics (NASDAQ:LUCD), 22nd Century Group (NASDAQ:XXII), and Safe Harbor Financial (NASDAQ:SHFS).

KBLB Moves Spider Silk into Commercial Applications

Kraig Biocraft Laboratories (OTCQB:KBLB) recently shipped its first commercial order of recombinant spider silk yarn to a globally recognized performance sports brand, for a confidential pilot development program.

Potential developments to watch include additional orders and any future disclosure of the customer or products using the material, as well as scientific updates from Project Atlas. In September, Kraig reported completing the foundational Atlas Gene Library, supporting its work on future spider silk fibers with targeted performance characteristics.

Kraig also announced that Chief Operating Officer Jon Rice has been invited to present at the International Sericultural Commission Congress in Chennai, India, November 23–27. His presentation is expected to address the commercial impact of genetic engineering on silk markets.

GPUS Reaffirms Its 2027 Revenue and Earnings Outlook

Hyperscale Data (NYSEAMERICAN:GPUS) drew heavy trading activity Friday after reaffirming preliminary consolidated 2027 guidance of $300 million to $350 million in revenue and $60 million to $80 million in adjusted EBITDA.

The company is developing AI data center infrastructure while also operating financial-services, digital-asset and diversified portfolio businesses. Its guidance covers those consolidated operations.

Management expects the first phase of AI compute capacity at its Michigan campus to be energized and begin generating revenue in December 2026. That milestone gives investors a near-term development to follow alongside the company’s broader 2027 outlook.

LUCD Begins Receiving Medicare Payments for EsoGuard

Lucid Diagnostics (NASDAQ:LUCD) announced that it’s receiving Medicare payments for its EsoGuard Esophageal DNA Test, a development that could support broader commercial adoption of its esophageal precancer testing technology.

The company said claims for tests performed at one of its two CLIA-certified laboratories are being paid at the established Medicare rate of $1,938.01 per test. Lucid also closed a $15 million private placement of Series C convertible preferred stock on October 21.

“Medicare is now paying for EsoGuard,” said Lishan Aklog, M.D., Lucid’s chairman and chief executive officer.

Aklog said reimbursement removes a key obstacle in discussions with large health systems. The financing is intended to support near-term commercial expansion, working capital and general corporate purposes.

XXII Sees Heavy Volume Following Preliminary Results

22nd Century Group (NASDAQ:XXII) attracted heavy early trading Friday after releasing preliminary third-quarter results.

The company, which develops and commercializes low-nicotine tobacco products, reported the following preliminary, unaudited figures for continuing operations for the quarter ended September 30, 2026:

·   Net revenue of approximately $4.8 million, up 66% from $2.9 million in the second quarter.

·   Gross profit of approximately $400,000, compared with a $300,000 gross loss in the second quarter.

·   Operating expenses of approximately $3 million, unchanged from the second quarter.

·   Operating loss and net loss of approximately $2.6 million each, compared with $3.3 million each in the second quarter.

·   Adjusted EBITDA loss of approximately $2.2 million, compared with a $3.5 million loss in the second quarter.

·   Cash and equivalents of $3.9 million at quarter-end.

The company also reported 3,416,441 common shares outstanding as of October 22, with no warrants remaining outstanding. Full third-quarter results are expected on or before November 13.

SHFS Trades Nearly One Billion Shares After Nasdaq Extension

SHF Holdings, doing business as Safe Harbor Financial (NASDAQ:SHFS), recorded approximately 956.6 million shares in reported trading volume on October 22. The stock finished that session up 122.37% at $0.3429.

The activity followed the company’s announcement that Nasdaq granted it an additional 180 days, through April 19, 2027, to regain compliance with the exchange’s $1 minimum bid-price requirement.

Safe Harbor operates a financial technology platform serving regulated cannabis and hemp businesses. Through a network of regulated financial institution partners, it provides access to banking, lending, payments and related business services.

About 24/7 Market News

In today’s fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.

PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is a third-party media provider that owns KBLB shares, which are on deposit and may be sold at the editor’s discretion, and has been compensated for providing ongoing KBLB market outreach and other services.. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. For further information, please visit 247marketnews.com or https://go.247marketnews.com/kblb-disclosure/

Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication.  Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.

CONTACT:
24/7 Market News
Editor@247mnn.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.